Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin crossover study in recently discharged patients with heart failure and type 2 diabetes
ACTRN12618001981213Phase 4Not yet recruiting
- Sponsor
- Flinders Medical Centre
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in heart failure (HF) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Flinders Medical Centre. Primary endpoint: Change in 6-minute walk test. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12618001981213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001981213.